Cara Therapeutics
CARA
$9.60
Share price
3.67%
Change (1 day)
-33.93%
Change (1 year)
Categories
Revenue for Cara Therapeutics (CARA)
Revenue in 2022 (TTM): $0.02 B
According to Cara Therapeutics 's latest financial reports the company's current revenue (TTM) is $0.02 B. In 2020 the company made a revenue of $0.13 B an increase over the years 2019 revenue that were of $0.01 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cara Therapeutics from 2014 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | $0.02 B | |
| 2020 | $0.13 B | 579.28% |
| 2019 | $0.01 B | |
| 2014 | $3.17 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $94.88 B | 366,472.65% | 🇺🇸 USA |
 Pfizer PFE | $92.36 B | 356,763.58% | 🇺🇸 USA |
 Trevena TRVN | $0.37 M | -98.54% | 🇺🇸 USA |
 Recro Pharma
REPH | $0.07 B | 191.16% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | $0.10 B | 287.90% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | $0.12 B | 374.22% | 🇺🇸 USA |
 AcelRx Pharmaceuticals
ACRX | $2.74 M | -89.38% | 🇺🇸 USA |